Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0020672 (
hypothermia
)
17,327
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Two series of experiments were done to investigate the mechanism underlying arginine8-vasopressin (AVP)-induced barrel rotation in rats. In the first series, the effect of intracerebroventricular (ICV) administration of various neurohypophyseal hormone antagonists on AVP-induced barrel rotation was studied. The more vasopressin was given, the more the rats exhibited barrel rotation. ICV pretreatment with a
V1 vasopressin receptor
antagonist, d(CH2)5[Tyr(Me)2]AVP, prevented barrel rotation, while similar treatment with a V2-antagonist, d(CH2)5[dIle2Ile4]AVP, did not affect vasopressin-induced barrel rotation. However, Des-Gly,NH2d(CH2)5[Tyr)Me2)Thr4Orn8]-vasotocin, a specific oxytocin antagonist, potentiated the effect of AVP on barrel rotation. The second experiment was performed in rats equipped with a telemetry system to measure heart rate (HR), core temperature (CT), and gross locomotor activity. Also, in this experiment the incidence of AVP-induced barrel rotation was dose-dependent, as was the number of rats that died. Barrel rotation was accompanied by a significant decrease in CT and HR, while rats that did not develop
hypothermia
did not show barrel rotation. These results suggest that a V1 receptor is involved in barrel rotation. Since AVP-induced
hypothermia
is also mediated by a V1 receptor, it is postulated that
hypothermia
is a prerequisite for barrel rotation to occur. Further experiments are needed to substantiate this hypothesis.
...
PMID:Barrel rotation induced by central arginine8-vasopressin treatment: involvement of neurohypophyseal peptide receptors. 811 25